Corrigendum to Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma. Am J Ophthalmol. 2026;285:318–323
Corrigendum to Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma. Am J Ophthalmol. 2026;285:318–323. // American Journal of Ophthalmology. – URL: https://www.sciencedirect.com/science/article/pii/S0002939426004010?dgcid=rss_sd_all
Corrigendum to Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma. Am J Ophthalmol. 2026;285:318–323. American Journal of Ophthalmology. https://www.sciencedirect.com/science/article/pii/S0002939426004010?dgcid=rss_sd_all
“Corrigendum to Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma. Am J Ophthalmol. 2026;285:318–323.” American Journal of Ophthalmology.
@article{article34450,
title = {Corrigendum to Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma. Am J Ophthalmol. 2026;285:318–323},
journal = {American Journal of Ophthalmology},
url = {https://www.sciencedirect.com/science/article/pii/S0002939426004010?dgcid=rss_sd_all}
}
Abstract Purpose To compare the efficacy of intravitreal dexamethasone (DEX) implant‐based regimen versus ranibizumab‐based regimen for managing retinal exudation and complications in stage 3 Coats' disease. Methods Thirty‐seven eyes...
Abstract Foundation models are rapidly emerging as a major development in ophthalmic artificial intelligence, largely because they can achieve strong downstream performance with fewer labelled images than conventional supervised models,...
Abstract Purpose To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. Methods This retrospective...